Longwood Fund, and Alta Partner, venture capital firms, led a $70m round in DEM BioPharma, an immuno-oncology company, with participation from Insight Partners, Pfizer Ventures, Astellas Venture Management, Emerson Collective, UTokyo Innovation Platform and Alexandria Venture Investments. “Currently known DEM signals have been described in an ad hoc manner. DEM Bio’s founders discovered a scalable approach to systematically unlock the potential of innate immune system checkpoints,” Christoph Westphal, DEM BioPharma CEO.